Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVTA

Unusual Options Activity in FUBO: 2700% In 1 Day?!

Inside FUBO's under the radar rally, and the unusual options activity that preceded the short squeeze.

4 Genomics Stocks to Consider Buying After the Crash

4 Genomics Stocks to Consider Buying After the Crash

The genomics industry is poised to grow significantly in 2022, driven by strong demand amid the increasing need for personalized medicine and the rising population with serious illnesses. Thus, beaten-down genomics stocks Invitae (NVTA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP) could be ideal investments now.

Analyst Ratings for Invitae

Analyst Ratings for Invitae

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Invitae

Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:

Is Invitae Stock a Buy Under $5?

Invitae's (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around the stock. However, given the company's widening losses and poor profitability, the question is, is it worth betting on the stock at the…

Recap: Invitae Q1 Earnings

Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.

4 Cathie Wood Stocks That Remain Sells Even After Falling by More Than 50%

Institutional investor Cathie Wood’s funds have been declining sharply over the past year amid a broad selloff in stocks due to macro headwinds, including skyrocketing inflation, the Fed’s hawkish monetary stance, climbing U.S. Treasury yields, and the consequences of intense economic sanctions imposed on Russia. Owing to their poor earnings…

inkl

Read news from The Economist, FT, and more,
with one subscription

Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation

Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation

Invitae Corp's (NASDAQ: NVTA)

3 Cathie Wood Stocks Down by More Than 50% From Their Highs

3 Cathie Wood Stocks Down by More Than 50% From Their Highs

Cathie Wood’s flagship fund, the ARK Innovation ETF (ARKK), gained in triple digit percentage terms during 2020, which propelled her to widespread notoriety. However, in 2021 the fund declined. Furthermore, short interest against ARKK has increased, and bets against her other funds are near record highs. Amid this, we think…

2 of Cathie Wood's Favorite Stocks That Still Have More Downside

2 of Cathie Wood's Favorite Stocks That Still Have More Downside

Cathie Wood’s ARK ETFs are significantly down this year. Wood’s holdings Roblox (RBLX) and Invitae (NVTA) have plunged over the past few months and we believe more downside in the months ahead.

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Teladoc Health Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

244,711 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play